IMMUCELL CORP /DE/ (ICCC)

↓ Download CSV

CIK 0000811641 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, IMMUCELL CORP /DE/ reported revenue of $27.64M, up 4.3% from the prior year. The company ran a net loss, with a net margin of -3.8% and a gross margin of 41.4%. It held $42.53M in total assets against $15.48M in total liabilities.

Key ratios (FY2025)

41.4%
Gross margin
6.0%
Operating margin
-3.8%
Net margin
-3.8%
Return on equity
+4.3%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$27.64M$26.49M$17.47M$18.57M
Cost of Revenue$16.20M$18.55M
Gross Profit$11.45M$7.94M$3.87M$7.65M$8.66M$6.86M$6.74M$5.19M$5.22M$5.42M
Operating Income$1.65M-$1.64M-$5.75M-$2.30M$257.4K-$1.38M-$953.9K-$1.45M-$242.8K$890.2K
Net Income-$1.04M-$2.16M-$5.77M-$2.49M-$78.3K-$1.02M-$1.30M-$2.32M-$168.1K$508.4K
EPS (Diluted)$-0.12$-0.26$-0.75$-0.32$-0.01$-0.14$-0.19$-0.42$-0.03$0.12
Total Assets$42.53M$45.10M$43.81M$44.86M$44.47M$40.35M$38.69M$32.73M$34.30M$24.70M
Total Liabilities$15.48M$17.58M$18.82M$14.48M$11.89M$12.08M$9.70M$10.99M$10.70M$4.98M
Shareholders' Equity$27.06M$27.52M$24.99M$30.38M$32.58M$28.27M$28.99M$21.74M$23.59M$19.72M
Cash & Equivalents$3.81M$3.76M$978.7K$5.79M$10.19M$6.95M$6.29M$2.52M$3.80M$5.15M
Operating Cash Flow$2.48M$357.9K-$4.67M-$1.54M$954.2K$1.32M$233.5K-$373.4K$1.18M-$222.3K
Capital Expenditures$1.25M$465.7K$1.89M$3.98M$2.61M$4.07M$1.39M$2.03M$17.76M$3.59M
Shares Outstanding9.03M8.17M7.75M7.75M7.59M7.21M6.82M5.49M4.95M4.34M